- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05204433
Correlation Between SFRP1 and Colorectal Cancer and Adenoma
January 11, 2022 updated by: Jie Liang, Xijing Hospital of Digestive Diseases
Correlation Between Methylation Site of SFRP1 Gene Promoter and Colorectal Cancer and Adenoma
In summary, our study demonstrated the methylation sites of SFRP1 gene promoter in patients with colorectal cancer and adenoma and found SFRP1_16_17_18 CpG site was good performance as a diagnostic marker of colorectal cancer.
Study Overview
Status
Enrolling by invitation
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
220
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710012
- Jie Liang
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
consecutive adult patients undergoing an outpatient endoscopy
Description
Inclusion Criteria:
- consecutive adult patients undergoing an outpatient endoscopy and histopathologically diagnosed as colorectal cancer or adenoma. Also, healthy individuals were invited to be enrolled.
Exclusion Criteria:
- Lynch syndrome
- Familial adenomatous polyposis
- MUTYH associated polyposis
- Peutz-Jeghers syndrome
- Juvenile polyposis syndrome
- Serrated polyposis syndrome
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
normal control
healthy volunteers
|
no intervention
|
|
adenoma
pathologically reported colorectal adenoma
|
no intervention
|
|
colorectcal cancer
pathologically reported colon cancers
|
no intervention
|
|
High risk group
pathologically reported inflammatory bowel diseases
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
effectiveness of methylation markers from stool samples
Time Frame: 3 years
|
assess the effectiveness of methylation markers from stool samples in colon cancer patients, colorectal adenoma patients, compared with normal volunteers
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
assess the capacities of RF model in screening potential clinical biomarkers.
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 5, 2019
Primary Completion (Anticipated)
February 20, 2022
Study Completion (Anticipated)
March 30, 2022
Study Registration Dates
First Submitted
January 11, 2022
First Submitted That Met QC Criteria
January 11, 2022
First Posted (Actual)
January 24, 2022
Study Record Updates
Last Update Posted (Actual)
January 24, 2022
Last Update Submitted That Met QC Criteria
January 11, 2022
Last Verified
January 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Adenoma
Other Study ID Numbers
- XJLJ-Fecal-adenoma
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.